MedWatch

Coloplast presents strong Q3 figures

The Danish medtech firm has just released its third quarterly report for fiscal 2021/2022, maintaining it full-year guidance while beating analysts’ expectations. (Updated)

Photo: Coloplast / PR

In the third quarter of financial 2021/2022, Coloplast managed to exceed expectations set by analysts prior to the report.

The Danish medtech company’s Q3 revenue of DKK 5,849m (USD 800m) is thus higher than the projected DKK 5,753m (USD 787m), while its net result of DKK 1,289m (USD 176m) also came in over the estimated DKK 1,249m (USD 171m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs